Management of Postmenopausal Vaginal Atrophy–Related Bleeding

Evaluation Before Treatment

• Prompt endometrial assessment (e.g., transvaginal ultrasound measurement of endometrial thickness and/or endometrial biopsy) is required in any postmenopausal woman with bleeding, even if she is using low‑dose vaginal estrogen, because vaginal estrogen does not eliminate the risk of endometrial cancer. 1

Non‑Hormonal First‑Line Therapy

• Vaginal moisturizers applied at least twice weekly are recommended as first‑line therapy to improve tissue hydration, reduce epithelial fragility, and lessen bleeding episodes. 1

Hormonal Therapy for Persistent Symptoms

• In patients whose bleeding persists despite adequate non‑hormonal measures, low‑dose vaginal estrogen (e.g., estradiol tablets) should be used to restore epithelial thickness and eliminate bleeding by reversing atrophic changes. 1

Expected Timeline of Clinical Improvement

• Clinical improvement typically begins within 2–3 weeks after initiating daily low‑dose vaginal estrogen, with continued normalization of the vaginal epithelium over a 12‑week period. 5

Critical Pitfall to Avoid

• Do not attribute postmenopausal bleeding to vaginal atrophy without first excluding endometrial pathology, as this can delay the diagnosis of endometrial cancer. 1